Comité del programa
-
Kazuhiko Ishida, MSC, RPH Director, Pharmacovigilance
Astellas Pharma Inc., Japan -
Hiroki Nagahama, MS Director, Japan Safety Risk Management Lead, Clinical Safety & Pharmacovigilance
GlaxoSmithKline K.K., Japan -
Aiko Kumano Reviewer, Office of Safety II
Pharmaceuticals and Medical Devices Agency (PMDA), Japan -
Hideo Nakada, RPH Deputy Associate Manager, Department of Hospital Pharmacy
Keio University, Japan -
Kasumi Daidoji, PHD, RPH Associate Director, Clinical Planning & Development Dept., Medical Headquarters
Eisai Company, Ltd., Japan -
Tomoko Yamada Director, Safety risk management, Pharmacovigilance
MSD K.K., Japan -
Emiko Iida, MPHARM
Daiichi Sankyo Co Ltd, Japan -
Akiko Nishioka Clinical Project Manager
Novartis Pharma K.K., Japan -
Toshifumi Sugizaki Reviewer, Office of New Drug I
Pharmaceuticals and Medical Devices Agency (PMDA), Japan -
Ayako Kurokawa
MSD K.K., Japan -
Shogo Nakamori, MBA, MSC, RPH Senior Vice President & Managing Director, DIA Japan, Korea, and Singapore
DIA, Japan
¿Tiene una cuenta?